Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Todd

Infectious Disease Shreveport, LA Medical Doctor

NPI 1730101205 CMS profile 168941

1501 Kings Hwy, Department Of Medicine Inf Diseases, Shreveport, LA 71103

Open in the dashboard

General payments

$3,551

154 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Todd of Shreveport, LA is reported in the CMS Open Payments database as having received $3,551 across 154 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $625 27
2024 General $531 26
2023 General $650 33
2022 General $711 31
2021 General $166 9
2020 General $180 6
2019 General $688 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Todd
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to John Todd were reported at $625. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year John Todd Infectious Disease median Middle half National median
2019 $688 $190 $60–$862 $163
2020 $180 $124 $32–$606 $114
2021 $166 $148 $38–$905 $132
2022 $711 $166 $50–$834 $149
2023 $650 $171 $57–$787 $160
2024 $531 $176 $52–$752 $164
2025 $625 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,023 43 payments
  2. Merck Sharp & Dohme Corporation $635 37 payments
  3. Insmed, Inc. $382 11 payments
  4. Paratek Pharmaceuticals, Inc. $323 10 payments
  5. Shionogi Inc $219 12 payments
  6. Astellas Pharma US Inc $217 11 payments
  7. ViiV Healthcare Company $175 10 payments
  8. Melinta Therapeutics, Inc. $132 6 payments
  9. Tetraphase Pharmaceuticals, Inc. $125 1 payment
  10. Allergan Inc. $89 2 payments
  11. Other $231 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,530 151 payments
  2. Education $20 3 payments
Products named General payments · program years 2019–2025
  1. AVYCAZ $759 33 payments
  2. DALVANCE $556 25 payments
  3. ZERBAXA $409 23 payments
  4. Arikayce $382 11 payments
  5. TEFLARO $348 16 payments
  6. NUZYRA $323 10 payments
  7. DIFICID $236 15 payments
  8. Fetroja $219 12 payments
  9. RECARBRIO $208 13 payments
  10. DOVATO $161 9 payments
  11. Other $1,761 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

154 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record